- The U.S. Department of Agriculture (USDA) approves the use of CPMA for passive immunity, allowing veterinarians to protect exposed puppies from canine parvovirus as a valuable, preventative option.
- To further the mission of Defend Puppies. Defeat Parvo., Elanco expands the availability of CPMA by donating more than $3 million of the product, enabling 2,300 clinics and shelters in high parvo areas to have their first experience with this life-saving treatment.
- 27 parvo-infected puppies were saved with the help of CPMA at the SPCA of Brevard Adoption Center in Florida, the largest recorded group to be saved by this treatment to date.
GREENFIELD, Ind. (June 27, 2025) – Elanco Animal Health Incorporated today announced several exciting milestones that further expand veterinarians’ efforts to Defend Puppies. Defeat Parvo. against the deadly canine parvovirus (parvo), a devastating disease that affects more than 330,000 puppies annually, with up to a staggering 91% mortality rate without supportive care i,ii. Canine Parvovirus Monoclonal Antibody (CPMA) is the first and only U.S. Department of Agriculture (USDA) conditionally approved treatment to target parvo. Most significantly, the USDA has approved the use of Canine Parvovirus Monoclonal Antibody (CPMA) for passive immunity (i.e., prophylactic treatment) to prevent parvo infection in puppies exposed to the virus, expanding the potential to protect dogs from this devastating disease.
To further the mission of Defend Puppies. Defeat Parvo., Elanco also expanded the availability of CPMA by donating more than $3 million of the product to 2,300 clinics and shelters in high parvo areas across the country. The sampling program helped shelters, veterinarians and pet owners have greater access to this life-saving treatment. In the last three months alone, the expanded availability of CPMA has increased the potential to save thousands of puppies’ lives, while providing shelters and clinics a firsthand opportunity to experience the treatment.
“We understand that pet owners and veterinarians are navigating rising costs and financial uncertainty right now, which is why we’re focused on making CPMA even more accessible to every puppy that needs it,” said Dr. Chris George, veterinarian and infectious disease expert at Elanco Animal Health. “The label expansion to include passive immunity, in addition to our $200 rebate program, and sampling programs to shelters and clinics in high parvovirus areas further advances our mission to defend puppies and defeat parvo, delivering value and peace of mind to veterinarians and pet owners alike.”
The expanded product label protects dogs who have been exposed to this deadly virus, including shelter environments where resources are often constrained. In a clinical study when given at a prophylactic dose, CPMA was 100% effective in the passive immunity of healthy dogs 8 weeks of age or older against parvo.iii
Recently, a Florida shelter treated and saved the lives of 27 parvo puppies using CPMA, the largest recorded group to be saved by this treatment to date. Puppies like Ohana, Zen and Omni are thriving and available for adoption, demonstrating the impact that this life-saving treatment can have on puppies across the country.
“Parvo is a very deadly, contagious virus, and unfortunately, a lot of puppies don't make it through. CPMA has saved so many puppies,” said Tom Baumann, shelter manager for the SPCA of Brevard Adoption Center in Florida. “Within three days of treatment, these puppies went from being lethargic and critically ill to eating on their own, having solid stools, and getting their energy back. What normally takes over a week of intensive supportive care was accomplished in just three days. Now we can finally snuggle and play with them, let them go outside and run and just be puppies again. Seeing them healthy and acting like normal puppies is incredible.”
Florida, Texas, Arizona, Georgia, Illinois, Indiana and New York have some of the highest reported cases of canine parvovirus outbreaks in the last year, according to ParvoTrack, the first-ever national online parvo tracking tool launched by Elanco in 2023.
“We no longer live in fear of a parvo outbreak. With both treatment and prevention options now available for puppies exposed to the virus, we have powerful tools to intervene earlier and more effectively,” said Dr. Meghan Herron, Senior Director of Behavior, Research, and Education at Gigi’s, a nonprofit working to make high-quality care accessible to every shelter dog. “The updated product label gives us the flexibility to protect puppies before they show signs of illness—offering them a real second chance at a healthy start and sparing shelters, veterinary teams, and families from the emotional and physical toll of this deadly, yet preventable disease.”
Prior to this expanded approval, veterinarians could treat active parvovirus infections only after puppies became sick. The expanded approval reinforces Elanco’s leadership in the monoclonal antibody space and strengthens its commitment to helping pets live longer, healthier lives.
To learn more about CPMA please visit DefeatParvo.com
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
i Elanco Animal Health. Data on File.
ii Sykes, JE. Canine Parvovirus Infections and Other Viral Enteritides. Canine and Feline Infectious Diseases. 2014:141-151
iii Elanco Animal Health. Data on File.
PM-US-25-1221
